d biopharmaceutical company with $500M in revenue in 2010. Currently a director of Human Genome Sciences, Zelos and PanOptica. Chairman and CEO of Ambit Biosciences; previously President of Research at Celgene, CEO of Novocell, CEO of Signal Therapeutics, and VP of Research at Wyeth. 25+ year career advising

lue Portion) (Total) Gross IRR Realized or Partially Realized Investments Acadia Phamaceuticals, Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9% Ambit Biosciences, Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1% Array Biopharma Inc. Therapeutics 2012 9.0 20.3 - 20.3 2.25 2.25 74.0% Audax Health Solution